ライフサイエンスコーパス: SUV

1 SUV at 60 min after injection, normalized for body weigh

2 SUV measurements were significantly higher in BG-OG, DDG

3 SUV ratio (SUVR) was determined at different imaging win

4 SUV ratio-1 (SUVR-1) over several time windows was compa

5 SUV was discretized to a fixed number of bins (32, 64, o

6 SUV(max) and SUV(mean) values of PDAC manifestations and

7 SUV(max) exhibited a positive correlation with Ki-67 acr

8 SUV(max) normalized for lean body mass (SUL(max)) was me

9 SUV(max) was measured for all lesions, and tumor-to-back

10 SUV(max) was on average 21% higher than PET/static when

11 SUV(max), SUV(mean), CAA, %ID, and visual grade were mod

12 SUV(mean) ranged from 1.9 to 7.4, whereas the SUV(max) r

13 SUV(peak) was 12% higher.

14 SUV, tumor-to-background ratio, total functional tumor v

15 SUVs in tumors have been suggested to be a measure of so

16 interclass correlation coefficient = 1.000; SUV(max): R (2) = 0.988, P < 0.001, interclass correlati

17 lated (PSMA(TV50): R (2) = 1.000, P < 0.001; SUV(max): R (2) = 0.988, P < 0.001).

18 lood levels (0.08 +/- 0.01 and 0.54 +/- 0.07 SUV, respectively), indicating that (18)F-CFA does not c

19 (68)Ga-PSMA-HBED-CC showed a wCV of 12%-14% SUV(max) and an RC of +/-33%-38% SUV(max) in bone and no

20 eak) for a sphere with a volume of 14 mm(3) (SUV(P14)) as optimal metrics of response to therapy.

21 of 12%-14% SUV(max) and an RC of +/-33%-38% SUV(max) in bone and nodal lesions.

22 Mean (18)F-FDG uptake and mean (18)F-AV-45 SUV ratio (SUVr) in regions of hypometabolism and elevat

23 The RC was +/-32.5% SUV(max) for bone lesions and +/-37.9% SUV(max) for noda

24 0.15 (0.04-0.31] before to 0.49 (0.20-0.59) SUV after surgery (P = 0.008).

25 The recommended threshold of 66% SUV(max) reduction for the identification of poor respon

26 alivary glands and spleen was 8.9% and 10.7% SUV(mean), respectively.

27 -FLT PET for baseline HCC detection was 73% (SUV(max), 9.7 +/- 3.0; tumor to liver ratio, 1.2 +/- 0.3

28 beit in a small cohort, with ECV (r = 0.873, SUV(max)).

29 32.5% SUV(max) for bone lesions and +/-37.9% SUV(max) for nodal lesions, meaning 95% of the normal va

30 ) and metabolic activity (SUV(peak), -51.9%; SUV(mean), -43.8%), as well as an increase of the ADC va

31 ther group did not significantly change (AAA SUV=0.86+/-0.17 and sham-control SUV=0.46+/-0.10), indep

32 ptake nearly twice that of nonruptured AAAs (SUV=0.73+/-0.11).

33 tion in size (-9.7%) and metabolic activity (SUV(peak), -51.9%; SUV(mean), -43.8%), as well as an inc

34 the maximum tumor size, metabolic activity (SUV), and diffusion restriction (apparent diffusion coef

35 An SUV(max) ratio of more than 2.2 for lesion to blood pool

36 An SUV(mean) higher than 13.7 (75th percentile) was associa

37 ns were a PSMA RADS rating of at least 4, an SUV(max) of at least 4.1, and SUV(max) ratios of at leas

38 egmentation using an SUV of 2.5 (SUV2.5), an SUV of 4.0 (SUV4.0), adaptive thresholding (A50P), 41% o

39 e readout for the 2-FDG PET study is only an SUV parameter, variability in LC is important, particula

40 d tool was applied for segmentation using an SUV of 2.5 (SUV2.5), an SUV of 4.0 (SUV4.0), adaptive th

41 in liver metastases and anal cancer, with an SUV(max) of 9.1 and 13.9, respectively.

42 t metastases at 1 h after injection, with an SUV(max) of more than 10.

43 at least 4, an SUV(max) of at least 4.1, and SUV(max) ratios of at least 2.11 for lesion to blood poo

44 oxelwise correlations (r(s)) between ADC and SUV revealed null or weak monotonic relationships (mean

45 Detection rates were determined, and SUV(max) was compared separately for (68)Ga-PSMA-11 and

46 Tumor positivity rates were determined, and SUV(max) was compared separately for each tracer.

47 d lesions, organ systems of involvement, and SUV(max) of each organ system for both tracers.

48 timated from noninvasive tracer kinetics and SUV ratio (SUVR) measured at different time points after

49 Similar results were obtained for %ID/L and SUV(mean) SUV(max) did not correlate with survival.

50 68)Ga-FAPI-46 was quantified by SUV(max) and SUV(mean) After comparison with standard imaging, change

51 1, respectively) and the lowest SUV(max) and SUV(mean) being in muscle (1.1 +/- 0.06 and 0.7 +/- 0.04

52 odistribution, with the highest SUV(max) and SUV(mean) being in the thyroid gland (30.3 +/- 2.2 and 2

53 l-tissue ratios calculated from SUV(max) and SUV(mean) Results: We found 822 concordant lesions (visi

54 SUV(max) and SUV(mean) values of PDAC manifestations and healthy orga

55 e and percentage differences in SUV(max) and SUV(mean) were calculated for all test-retest regions.

56 Tumor SUVs (SUV(max) and SUV(mean)) were measured, and tumor burden was analyzed

57 Tumor SUVs (SUV(max) and SUV(peak)) were determined relative to SUV based on the

58 l, and muscle was quantified as SUV(max) and SUV(peak), and a descriptive analysis of the PET/CT imag

59 /mL), partial-volume-corrected SUV(max), and SUV ratios were tested against Ki-67.

60 Conclusion: PSMA RADS rating, SUV(max), and SUV(max) ratio for lesion to blood pool can help differe

61 The metabolic volume, SUV(max), and SUV(mean) of lesions were compared among the reconstruct

62 The SUV(mean) and SUV(max) of organs were measured with spheric volumes of

63 phenomena, the combined ratio of PET/MRI and SUV(mean)/ADC(min) may be used as a novel biomarker allo

64 ated independent associations between OS and SUV(mean) (P = 0.016) and IBI (P = 0.015).

65 or-to-blood ratio; SUV(mean), SUV(peak), and SUV(max) normalized to body weight; tumor volume; and to

66 For SUV(mean), SUV(peak), and SUV(max), the RCs were 24.4%, 25.3%, and 31.0%, respecti

67 RC variability decreased by 13% points, and SUV accuracy improved to 10%.

68 ubtype of OC, but clinical staging, TLG, and SUV(max) values were not related with histological subty

69 rimary difference between folding in NDs and SUVs was the kinetics; the rate of folding was two- to t

70 ircular dichroism spectra of OmpA in NDs and SUVs were similar and indicated beta-barrel secondary st

71 yields were greater than 88% in both NDs and SUVs.

72 cer concentrations in the brain (measured as SUV) for tobacco smokers than for nonsmokers by demonstr

73 VM, blood pool, and muscle was quantified as SUV(max) and SUV(peak), and a descriptive analysis of th

74 ccuracy of simplified uptake metrics such as SUV was investigated.

75 th conventional quantitative metrics such as SUV, metabolic tumour volume, and total lesion glycolysi

76 oup analysis, a significantly higher average SUV(mean) was seen for both pheochromocytoma and paragan

77 Results: At all time points, average SUV(max) was highest in the liver.

78 ic feature repeatability correlates with BAT SUV(max) repeatability, participants were stratified bas

79 We observed a weak correlation between SUV(max) and biopsy ISUP grade (rho = 0.21; P < 0.001) a

80 P < 0.001) and a modest correlation between SUV(max) and postprostatectomy ISUP grade (rho = 0.38; P

81 x) to liver, blood pool, and background bone SUV(max) Differences between benign and malignant lesion

82 mide treatment, an increase in total burden (SUV(total)) was seen at the time of progression, as meas

83 ), a serine-threonine kinase is activated by SUV irradiation and involved in skin carcinogenesis.

84 Assessment Score favors SUV(25) followed by SUV(peak) for a sphere with a volume of 14 mm(3) (SUV(P1

85 FAPI-04 and (68)Ga-FAPI-46 was quantified by SUV(max) and SUV(mean) After comparison with standard im

86 of interest were manually drawn to calculate SUVs.

87 tly higher changes in regional and composite SUV ratio (SUVR) over time (P = 0.0002 for composite SUV

88 Conclusion: SUV measurements from uPAR PET in primary tumors, as del

89 change (AAA SUV=0.86+/-0.17 and sham-control SUV=0.46+/-0.10), independent of variations in aortic di

90 ET positivity: comparison with young-control SUV ratios (SUVRs), receiver-operating-characteristic (R

91 s approximately twice that of sham-controls (SUV=0.47+/-0.10; P<0.01).

92 Partial-volume-corrected SUV(max) was positively correlated with Ki-67 for invasi

93 nge, 1.3-3.3 g/mL), partial-volume-corrected SUV(max), and SUV ratios were tested against Ki-67.

94 iautomatically delineated using a customized SUV threshold-based approach.

95 Results: The ratio of PET-derived SUV(mean) and diffusion-weighted imaging-derived minimum

96 mm voxels) for both scanners and determined SUV(max), SUV(mean), lesion-to-background ratio (LBR), m

97 this study, various functional 3-dimensional SUV apparent diffusion coefficient (ADC) parameters and

98 mine the predictive value of (64)Cu-DOTATATE SUV(max) for OS and PFS.

99 On dPET, SUV(mean), SUV(max), and LBR increased by 24%, 23%, and

100 the TLV multiplied by the average SUL (i.e., SUV normalized for lean mass) of the tumor (SUL(average)

101 (mean), cardiac amyloid activity (CAA; i.e., SUV(mean) x left ventricular [LV] volume), and percentag

102 uantitative Response Assessment Score favors SUV(25) followed by SUV(peak) for a sphere with a volume

103 to monitor change over time using the 2-FDG SUV metric.

104 rating-characteristic analysis, an (18)F-FDG SUV of more than 2.5 was most accurate to identify smear

105 One-month (18)F-FDG-SUV decreased by 86%; CRR was 63% (95% CI 44-79%).

106 For SUV(mean), SUV(peak), and SUV(max), the RCs were 24.4%,

107 tion for SUV(max), %ID, and CAA and 3.8% for SUV(mean) All 4 quantitative metrics had a standardized

108 for tumor size, 0.87 for SUV(peak), 0.82 for SUV(mean), 0.63 for ADC(min), 0.84 for ADC(mean), and 0.

109 ding AUCs were 0.63 for tumor size, 0.87 for SUV(peak), 0.82 for SUV(mean), 0.63 for ADC(min), 0.84 f

110 less than a 2% coefficient of variation for SUV(max), %ID, and CAA and 3.8% for SUV(mean) All 4 quan

111 The wCV for SUV(max) was 11.7% for bone lesions and 13.7% for nodes.

112 umor-to-normal-tissue ratios calculated from SUV(max) and SUV(mean) Results: We found 822 concordant

113 rmation regarding BAT activity distinct from SUV(max) These features might be explored as quantitativ

114 tified into the high-Ki-67 (>=20%) group had SUV(max) greater than the low-Ki-67 (<20%) group (P = 0.

115 est metastatic node while 4 normal nodes had SUV > 4.5.

116 Tumors with a high SUV in vivo also showed a high immunohistochemical stain

117 le, stable biodistribution, with the highest SUV(max) and SUV(mean) being in the thyroid gland (30.3

118 However, SUVs in tumors do not correlate with the net influx rate

119 sponders were -6.2% in tumor size, -17.3% in SUV(peak), -13.9% in SUV(mean), +15.3% in ADC(min), and

120 n tumor size, -17.3% in SUV(peak), -13.9% in SUV(mean), +15.3% in ADC(min), and +14.6% in ADC(mean) C

121 visual 5-point scale (5-PS) and a change in SUV (DeltaSUV) by semiquantitative evaluation.

122 t predictor of PSA progression was change in SUV(hetero) (PET1 to PET3; hazard ratio, 3.88; 95% CI, 1

123 ADC(min), and +14.6% in ADC(mean) Changes in SUV and ADC(mean) significantly differed between respond

124 priori, there was a significant decrease in SUV(max) corrected for lean body mass (SUL(max)) on imag

125 On early interim PET, a decrease in SUV(mean) of more than 17% (75th percentile) was associa

126 ratified based on the relative difference in SUV(max) between sessions.

127 Absolute and percentage differences in SUV(max) and SUV(mean) were calculated for all test-rete

128 ticipants with lower relative differences in SUV(max) between initial and repeated imaging sessions h

129 gated, DDG-retro gave an average increase in SUV(max) of 0.66 +/- 0.1 g/mL (n = 87, P < 0.0005).

130 Second, a measured increase in SUV(max) of 39% or more, or a decrease of 28% or more, i

131 UV(max) criterion of a relative reduction in SUV(max) of less than or equal to 66% should be consider

132 nstruction method type followed the trend in SUV(max), as participants with lower relative difference

133 o- to threefold slower in NDs compared to in SUVs, and this decreased rate can tentatively be attribu

134 Seven features, including SUV(max,) did not cluster with any other features.

135 Metabolic parameters including SUV(max), metabolic tumor volume, and total lesion glyco

136 , with a median intraarterial-to-intravenous SUV(max) ratio of 0.81 (range, 0.36-2.09) on a lesion le

137 nt images did not show differences in lesion SUV(max) or SUV(peak) between scan durations.

138 Significant differences in lesion SUV(max) were found between the 180-s/bp images and the

139 whereas no differences were found in lesion SUV(peak) EARL-compliant images did not show differences

140 We measured lesion SUV(max), reference normal-organ or -tissue SUV(mean), a

141 (RADS) rating; SUV(max); and ratio of lesion SUV(max) to liver, blood pool, and background bone SUV(m

142 were a total of 254 (18)F-FES-avid lesions (SUV(max), 2.6-17.9) and 111 (18)F-FDG-avid lesions (SUV(

143 ), 2.6-17.9) and 111 (18)F-FDG-avid lesions (SUV(max), 3.3-9.9) suggestive of malignancy.

144 take colocalizing with inflammatory lesions (SUV(mean), 2.1 +/- 1.1), whereas uptake in the remote my

145 ues with tracer uptake, potentially limiting SUV quantification.

146 ented by a percental threshold (50% of local SUV(max)).

147 dium of immunized rats and controls was low (SUV(mean), 0.4 +/- 0.2 and 0.4 +/- 0.1, respectively; P

148 resulting in higher image quality and lower SUV bias and variance than for FD PET PIS.

149 The Bland-Altman plots reported the lowest SUV bias (0.02) and variance (95% confidence interval, -

150 d 10.1 +/- 1.1, respectively) and the lowest SUV(max) and SUV(mean) being in muscle (1.1 +/- 0.06 and

151 suggest that a threshold of 25% of SUV(max) (SUV(25)) was highly reproducible (<9% variability).

152 le-body tumor volume (PSMA(TV50)), SUV(max), SUV(mean), and other whole-body imaging biomarkers were

153 glycolysis, as well as peritumoral SUV(max), SUV(mean), and their respective ratios to background, we

154 SUV(max), SUV(mean), CAA, %ID, and visual grade were moderately po

155 m-zinc-telluride SPECT/CT scanner, SUV(max), SUV(mean), CAA, and %ID measured by absolute quantitatio

156 For 72 patients, SUV(max), SUV(mean), cardiac amyloid activity (CAA; i.e., SUV(mean

157 ) for both scanners and determined SUV(max), SUV(mean), lesion-to-background ratio (LBR), metabolic t

158 tabolic variables, including tumor SUV(max), SUV(mean), metabolic tumor volume, and total lesion glyc

159 Despite equivalent tumor SUV(max), SUV(mean,) and total tumor volume, total lesion activity

160 Tracer uptake was determined as the maximal SUV (SUV(max)) for each patient.

161 Mean and maximal SUVs and ratios to nontumor tissue in the contralateral

162 Differences in minimum ADC and maximum SUV between responders and nonresponders and comparison

163 colytic activity as reflected by the maximum SUV (SUV(max)) is measurable from FDG PET/CT with a with

164 cal response prediction according to maximum SUV (area under the receiver operating characteristic cu

165 a significant uptake with increasing maximum SUVs (SUV(max) at 2 h after injection: 4.3-25.9) over ti

166 root mean square error (0.21 +/- 0.05 [mean SUV +/- standard deviation]), mean peak signal-to-noise

167 VM lesions (mean SUV(max), 3.0 +/- 1.1; mean SUV(peak), 2.2 +/- 0.9).

168 wed enhanced uptake in all AVM lesions (mean SUV(max), 3.0 +/- 1.1; mean SUV(peak), 2.2 +/- 0.9).

169 The mean SUV(max) before and after correction was 11.0 +/- 9.3 an

170 esults were obtained for %ID/L and SUV(mean) SUV(max) did not correlate with survival.

171 On dPET, SUV(mean), SUV(max), and LBR increased by 24%, 23%, and 27%, respec

172 Mean (+/-SD) SUV(mean), SUV(max,) LBR, and MTV on cPET were 5.2 +/- 3.9, 6.9 +/-

173 and maximum tumor-to-blood ratio; SUV(mean), SUV(peak), and SUV(max) normalized to body weight; tumor

174 For SUV(mean), SUV(peak), and SUV(max), the RCs were 24.4%, 25.3%, and

175 From the simplified measures, SUV normalized for body weight at 50 and 67 min after in

176 Median SUV(max) of benign and malignant lesions was 3.8 (IQR, 3

177 OCO than in static images (P < 0.001; median SUV(max): static, 14.3 +/- 13.4; BG-EMOCO, 19.8 +/- 15.7

178 7 tumor lesions were analyzed, with a median SUV(peak) of 1.4 (range, 0.7-2.3) and tumor-to-blood rat

179 The median SUV(max) across all lesions was 11.6 (range, 1.5-57.6).

180 The median SUV(mean) of benign and malignant lesions was 2.3 (inter

181 Bq/kg) were evaluated using several metrics: SUV quantitation, qualitative image quality, and lesion

182 The SUV(55 min) (SUV during the last 10-min time frame, 50-60 min after a

183 Myocardial SUV(max) decreased at follow-up (6.5 to 4.0; P < .01) an

184 with an adverse outcome (P = 0.001 for nodal SUV above vs. below median).

185 and r (patientwise)) between the normalized SUV (nSUV), rCBV, and ADC were evaluated.

186 on, whereas the other 3 women (30%) did not (SUV ratio <= 1.0).

187 Our data suggest that a threshold of 25% of SUV(max) (SUV(25)) was highly reproducible (<9% variabil

188 UV4.0), adaptive thresholding (A50P), 41% of SUV(max) (41%), a majority vote including voxels detecte

189 semiquantitatively evaluated on the basis of SUV at each time point.

190 fications were also used for measurements of SUV in tumor lesions and healthy tissues for comparison

191 two complementary claims on the precision of SUV measurements.

192 The repeatability of SUV(peak), TLU, and all patient-level metrics was not af

193 rranted to fully characterize the utility of SUV(25) and preclinical PERCIST SUV(P14) as image metric

194 checkpoint inhibition, further validation of SUV against V (T) based on an image-derived input functi

195 re quantitatively assessed for comparison of SUVs and noise.

196 semiquantitative analysis by measurement of SUVs in tumor lesions.

197 nuous DeltaSUV(max) scale, which is based on SUV(max) changes between baseline and interim scans.

198 A composite score based on SUV(mean) and IBI allowed us to further stratify patient

199 B had an RC of 23.2% and 33.4% when based on SUV(mean) and mean tumor-to-blood ratio, respectively.

200 ogous to the temperature-jump experiments on SUVs.

201 m nondiseased prostate segments, and optimal SUV cutoffs were calculated using the Youden index for e

202 d not show differences in lesion SUV(max) or SUV(peak) between scan durations.

203 terest were used to measure the SUV(mean) or SUV(max) of the tumor lesions.

204 racted from VOI(WT) Changes in voxel size or SUV discretization parameters typically resulted in rela

205 Tumor and organ SUV(mean) decreased over time, whereas TBRs in all organ

206 )), and TBR (tumor SUV(max)/background organ SUV(mean)) using muscle (T/M), bladder (T/B), and intest

207 also obtained for TBR (tumor SUV(max)/organ SUV(mean)).

208 y, pelvic lymph node TLG, PALN TLG, and PALN SUV(max) were significantly associated with OS (P < 0.00

209 Pancreas SUV ratio minus 1 (SUVR-1) (20-30 min; spleen as referen

210 ET- and MRI-derived quantitative parameters (SUV and ADC(mean)) and their combination performed well

211 For 72 patients, SUV(max), SUV(mean), cardiac amyloid activity (CAA; i.e.

212 to PERCIST1 and PERCIST5 (analyzing the peak SUV normalized by lean body mass [SUL(peak)] of 1 or up

213 e utility of SUV(25) and preclinical PERCIST SUV(P14) as image metrics for response to therapy across

214 al lesion glycolysis, as well as peritumoral SUV(max), SUV(mean), and their respective ratios to back

215 ectively (95%CI, 0.96-1.00), for peritumoral SUV(max) and 94%, 88%, and 0.96, respectively (95%CI, 0.

216 ectively (95%CI, 0.92-1.00), for peritumoral SUV(mean) (all P <= 0.025).

217 ptimize the reproducibility of (18)F-FDG PET SUV thresholds, SUV(peak) metrics, and preclinical PERCI

218 To simplify the scan protocol, SUV ratios (SUVRs) were compared with model-based nondis

219 PSMA SUV(max) and metastatic findings were compared with pros

220 Conclusion: PSMA RADS rating, SUV(max), and SUV(max) ratio for lesion to blood pool ca

221 SMA Reporting and Data System (RADS) rating; SUV(max); and ratio of lesion SUV(max) to liver, blood p

222 ean, peak, and maximum tumor-to-blood ratio; SUV(mean), SUV(peak), and SUV(max) normalized to body we

223 oss all subjects and 12 gray matter regions) SUV difference for (18)F-FDG (3.7% +/- 5.4% for (11)C-UC

224 l similarity index metric (SSIM), regionwise SUV bias, and first-, second- and high-order texture rad

225 r uptake in AAAs that subsequently ruptured (SUV=1.31+/-0.14; P<0.005) demonstrated uptake nearly twi

226 vel cadmium-zinc-telluride SPECT/CT scanner, SUV(max), SUV(mean), CAA, and %ID measured by absolute q

227 Mean (+/-SD) SUV(mean), SUV(max,) LBR, and MTV on cPET were 5.2 +/- 3

228 uded tumor-to-blood ratio as well as several SUV measures.

229 er uptake was determined as the maximal SUV (SUV(max)) for each patient.

230 ic activity as reflected by the maximum SUV (SUV(max)) is measurable from FDG PET/CT with a within-su

231 ificant uptake with increasing maximum SUVs (SUV(max) at 2 h after injection: 4.3-25.9) over time was

232 Tumor SUVs (SUV(max) and SUV(mean)) were measured, and tumor burden

233 Tumor SUVs (SUV(max) and SUV(peak)) were determined relative to SUV

234 In total, 16 unique PET (V(T), SUV) and MRI derived quantitative parameters were evalua

235 of (18)F-FACBC PET derived parameters (V(T), SUV) to DWI and RAFF derived parameters did not improve

236 volume-of-interest quantitation showed that SUVs remain stable down to 1/3 dose (1.2 MBq/kg).

237 The SUV ratio relative to breast around tumor was indistingu

238 The SUV(55 min) (SUV during the last 10-min time frame, 50-6

239 The SUV(max) of (18)F-rhPSMA-7 and (68)Ga-PSMA-11 did not di

240 The SUV(max) of lesions attributed to a benign origin was si

241 The SUV(mean) and SUV(max) of organs were measured with sphe

242 arametric MRI (mpMRI) was performed, and the SUV in the primary tumor, as delineated by mpMRI, was me

243 applying the visual Deauville score and the SUV-based qPET (q = quantitative) and DeltaSUV(max) scal

244 The correlation between the SUV and the Gleason score obtained by biopsy was assesse

245 ex, primary tumor site, and tumor grade, the SUV(max) cutoff hazard ratio was 0.50 (range, 0.32-0.77)

246 onstruction options, DDG-retro increased the SUV(max) and decreased the threshold-defined lesion volu

247 volumes of interest were used to measure the SUV(mean) or SUV(max) of the tumor lesions.

248 characterized as a relative reduction of the SUV(max) between baseline and iPET staging of less than

249 In the same 5 of 7 patients, the SUV(max) of (18)F-FES-avid lesions was greater than the

250 For each region, the SUV(max) of the lesion with the highest PSMA ligand upta

251 For each region, the SUV(max) of the lesion with the highest PSMA-ligand upta

252 (18)F-FES-avid lesions was greater than the SUV(max) of (18)F-FDG-avid lesions.

253 UV(mean) ranged from 1.9 to 7.4, whereas the SUV(max) range was 18-248.

254 or uptake, which in turn correlated with the SUV of metabolic tumor.

255 Furthermore, the SUVs in tumor lesions and healthy tissues agreed well (w

256 tric measure of myocardium above a threshold SUV (cardiac metabolic volume) decreased from a mean of

257 oducibility of (18)F-FDG PET SUV thresholds, SUV(peak) metrics, and preclinical PERCIST parameters.

258 SUV(max), reference normal-organ or -tissue SUV(mean), and tumor-to-normal-tissue ratios calculated

259 DC(mean), and 0.89 for ratio of ADC(mean) to SUV(peak) Conclusion: PET- and MRI-derived quantitative

260 ) and SUV(peak)) were determined relative to SUV based on the static method.

261 that NDs may be an excellent alternative to SUVs for folding experiments and offer benefits of optic

262 ained immediately after each scan, scaled to SUVs.

263 rated increased mean focal uptake of tracer (SUV ratio > 1.1) coinciding with the mammographic locati

264 d intraarterial (68)Ga-DOTATOC PET/CT, tumor SUV(max) was compared between intravenous and intraarter

265 Despite equivalent tumor SUV(max), SUV(mean,) and total tumor volume, total lesio

266 Metabolic variables, including tumor SUV(max), SUV(mean), metabolic tumor volume, and total l

267 Results: Tumor SUV(max) (median, 2.0 g/mL; range, 1.3-3.3 g/mL), partia

268 Tumor uptake (SUV(max)), and TBR (tumor SUV(max)/background organ SUV(mean)) using muscle (T/M),

269 blood pool were also obtained for TBR (tumor SUV(max)/organ SUV(mean)).

270 A cutoff for the tumor SUV(max) could be established with a sensitivity of 96%

271 lation with the Gleason score, and the tumor SUV(max) was able to discriminate between low-risk Gleas

272 Tumor SUVs (SUV(max) and SUV(mean)) were measured, and tumor b

273 Tumor SUVs (SUV(max) and SUV(peak)) were determined relative t

274 The whole-body tumor volume (PSMA(TV50)), SUV(max), SUV(mean), and other whole-body imaging biomar

275 inoma (cSCC) is caused by solar ultraviolet (SUV) exposure and is the most common cancer in the Unite

276 blocking significantly decreased AAA uptake (SUV=0.42+/-0.09).

277 e of 0.84 and 0.70, both (68)Ga-PSMA uptake (SUV(max)) and radiodensity (mean Hounsfield units) were

278 Tumor uptake (SUV(max)), and TBR (tumor SUV(max)/background organ SUV(

279 cal subtypes of OC on standard uptake value (SUV(max)), metabolic tumour volume (MTV), and total lesi

280 r(s)) between the standardized uptake value (SUV) and ADC data corrected for distortion were computed

281 n general, global standardized uptake value (SUV) metrics decreased while on enzalutamide (PET2) and

282 eproducibility of standardized uptake value (SUV) metrics to assess response to therapy, and we optim

283 with a threshold standardised uptake value (SUV) of 3.

284 ated by using the standardized uptake value (SUV) of the normalized root mean square error, the peak

285 ADCs) and maximum standardized uptake value (SUV) of up to six target lesions and assessed therapy re

286 yocardial maximum standardized uptake value [SUV(max)] > 3.6) in 17 of 22 patients who were subsequen

287 uptake from a median (standard uptake value [SUV]) 1.75 (interquartile range 1.39-2.57) before to 1.0

288 diotracer uptake (standardized uptake value [SUV]=0.91+/-0.25) was approximately twice that of sham-c

289 ed (maximum of 43%), standard uptake values (SUVs) were biased by a maximum of 44%.

290 e variability of standardized uptake values (SUVs).

291 embranes such as small unilamellar vesicles (SUVs) and planar lipid bilayers.

292 t alternative to small unilamellar vesicles (SUVs) for studies of membrane protein structure, but it

293 The metabolic volume, SUV(max), and SUV(mean) of lesions were compared among t

294 SUV at 30 min (Spearman rho = 0.71) and with SUV at 190 min (rho = 0.51).

295 constant that was most correlated both with SUV at 30 min (Spearman rho = 0.71) and with SUV at 190

296 me of distribution (V(T)) were compared with SUV ratio (SUVR) images from 40 to 60 min after injectio

297 = 2.8 and exhibited a high correlation with SUV(25) measures of tumor uptake, which in turn correlat

298 ro relations (95% confidence interval), with SUV averages from all users giving a slope of 0.96 +/- 0

299 observed between histological subtypes with SUV(max), overall survival (OS), or progression-free sur

300 early in patients receiving treatment, with SUV ranging from 5.85 to 22.8 in 6 target lesions.